Prospective Data Collection Initiative on Colorectal Cancer (PLCRC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02070146|
Recruitment Status : Recruiting
First Posted : February 25, 2014
Last Update Posted : January 15, 2019
Survival after colorectal cancer (CRC) diagnosis strongly depends on local tumor extent, lymph node involvement and the presence of distant metastases. However, there remains great inter-patient variability regarding treatment outcome. A combination of biochemical factors, histopathological features, genomic profile, environmental factors and other clinical factors are likely to influence prognosis and treatment effect, independent from tumor stage, but it is still unclear which, how, and to what extent these factors can influence tumor recurrence and mortality in both early stage (I-III) and late stage (IV) CRC.
Although the results from prospective clinical trials will remain the backbone of evidence based medicine, this concerns a highly selected patient population since the large majority (85%-95%) of cancer patients do not participate in clinical trials for various reasons. It is unlikely that trial participation will significantly improve in the near future. This fact has the following implications: 1) It is highly desirable to validate the results from trials in the general patient population. However, this is complicated by the fact that the documentation of patients treated in general practice (i.e. outside the scope of clinical trials) is largely insufficient to provide comparable patient cohorts in terms of prognostic characteristics and treatment parameters. 2) There is an increased availability of novel technologies that provide molecular markers with potential prognostic and/or predictive value. To test the clinical value of these markers large numbers of patients are required which greatly exceeds the number of patients who consent to participate in prospective clinical trials. 3) as a result of rapid technical developments, a range of new minimally invasive treatment options for CRC are entering the market. These interventions have the potential to be of great benefit for patients in terms of improved local control, higher probability of complete tumor removal, less damage to surrounding tissue, faster recovery and less short and long term side effects. Still, the interventions will have to prove their effectiveness, safety and superiority (or non-inferiority) to standard cancer treatments on a patient level. A prospective observational cohort study has the great opportunity to fill this gap.
|Condition or disease|
- To start a prospective observational cohort study of CRC patients from their primary diagnosis until death.
- After obtaining Informed Consent, to prospectively collect data on medical history, serious comorbidities, baseline clinical parameters, imaging results, pathology results, tumor characteristics, treatment, treatment outcomes, hospital stays, interventions and grade 3/4 adverse events.
- After obtaining separate Informed Consent for biobanking, to store blood and tumor tissue material, obtained during routine practice, in the biobank.
- The cohort will serve as an infrastructure geared towards efficient, safe and comprehensive clinical evaluation of new (image guided) interventions for treatment of CRC.
- More accurate data on the treatment and clinical and patient reported outcomes of CRC in daily practice.
- A continuous infrastructure for a large variety of research purposes including:
A. Prognostic research B. Biological research and (epi)genetic research C. Studies that compare new therapies in a target population according to the cohort multiple randomized controlled trial design. D. Health care policies and cost-effectiveness studies
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||10000 participants|
|Target Follow-Up Duration:||50 Years|
|Official Title:||Prospective Data Collection Initiative on Colorectal Cancer - a Prospective Observational Cohort Study -|
|Study Start Date :||May 2013|
|Estimated Primary Completion Date :||January 2050|
|Estimated Study Completion Date :||January 2051|
- Progression free survival [ Time Frame: up to 10 years ]
- Health related quality of life [ Time Frame: 3, 6, 12, 24, 36, 48 months ]measured by EORTC QLQ questionnaire
- Grade 3/4 (serious) adverse events [ Time Frame: 3 months ]
- Disease free survival [ Time Frame: up to 10 years ]
- Overall survival [ Time Frame: up to 10 years ]
- Work Ability Index (WAI) [ Time Frame: 3, 6, 12, 24, 36, 48 months ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02070146
|Contact: Miriam Koopman, MD, PhDemail@example.com|
Show 53 Study Locations
|Principal Investigator:||Miriam Koopman, MD, PhD||UMC Utrecht|
|Principal Investigator:||Lenny HM Verkooijen, MD, PhD||UMC Utrecht|
|Principal Investigator:||Martijn GH van Oijen, PhD||AIDS Malignancy Consortium|
|Principal Investigator:||Peter D Siersema, MD, PhD||Radboud University|